PDCD1 and neoplasm: The combination of the CD11b agonist ADH-503 with anti-PD-1 immunotherapy and chemotherapy results in a substantial decrease in tumor cell viability, proliferation, metabolic activity, immunomodulation, and the release of immunosuppressive and tumor-promoting cytokines (239).